

SUPPLEMENTARY FIGURE 4




Figure S4. Differences in SCU patients before and after treatment (N=9) with omalizumab (N=9). Percentages of (A) CD4 naïve ((CD3⁺CD4⁺CD27⁺CCR7⁺CD45RA⁺), (B) activated CD4 (CD3⁺CD4⁺HLA-DR⁺CD38⁻), (C) Th1 Central Memory (CD3⁺CD4⁺CCR7⁺CD45RA⁻CXCR3⁺CCR6⁻), (D) Th1 Effector Memory (CD3⁺CD4⁺CCR7⁺CD45RA⁻CXCR3⁺CCR6⁻), (E) activated CD4 (CD3⁺CD4⁺HLA-DR⁺CD38⁺) T cells in peripheral blood in patients before and 6 months after treatment with omalizumab (n=9).